AtriCure (ATRC) Set to Announce Quarterly Earnings on Wednesday

AtriCure (NASDAQ:ATRC) will be issuing its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, February 15th. The medical device company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.01. The firm had revenue of $106.50 million during the quarter, compared to the consensus estimate of $103.68 million. AtriCure had a negative return on equity of 7.55% and a negative net margin of 7.62%. The company’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.09) earnings per share. On average, analysts expect AtriCure to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AtriCure Stock Up 2.0 %

Shares of NASDAQ:ATRC opened at $23.17 on Wednesday. The business’s 50 day moving average is $30.44 and its 200 day moving average is $33.92. AtriCure has a 12-month low of $22.27 and a 12-month high of $59.61. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -35.11 and a beta of 1.38. The company has a quick ratio of 2.66, a current ratio of 3.57 and a debt-to-equity ratio of 0.15.

Analysts Set New Price Targets

Several analysts have recently issued reports on ATRC shares. StockNews.com lowered shares of AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, March 27th. Needham & Company LLC reissued a “buy” rating and set a $46.00 target price on shares of AtriCure in a research report on Wednesday, April 10th. UBS Group upped their target price on AtriCure from $57.00 to $58.00 and gave the company a “buy” rating in a report on Friday, February 16th. Oppenheimer upgraded AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 price target on the stock in a report on Tuesday. Finally, Stifel Nicolaus cut their price objective on AtriCure from $50.00 to $42.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat.com, AtriCure currently has a consensus rating of “Moderate Buy” and an average target price of $52.63.

Insider Activity at AtriCure

In other AtriCure news, insider Justin J. Noznesky sold 1,500 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $36.72, for a total value of $55,080.00. Following the completion of the sale, the insider now directly owns 74,284 shares of the company’s stock, valued at $2,727,708.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Karl S. Dahlquist sold 1,885 shares of AtriCure stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $32.16, for a total value of $60,621.60. Following the completion of the transaction, the insider now owns 50,954 shares in the company, valued at $1,638,680.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Justin J. Noznesky sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $36.72, for a total transaction of $55,080.00. Following the completion of the sale, the insider now directly owns 74,284 shares in the company, valued at approximately $2,727,708.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,116 shares of company stock worth $468,797. Insiders own 3.20% of the company’s stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.